Addition of Vandetanib to Standard Therapy (Pegliposomal Doxorubicin) in Patients With Recurrent Ovarian Cancer. A Multicentre Phase I / Randomized Phase II Study.

Trial Profile

Addition of Vandetanib to Standard Therapy (Pegliposomal Doxorubicin) in Patients With Recurrent Ovarian Cancer. A Multicentre Phase I / Randomized Phase II Study.

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 13 Oct 2016

At a glance

  • Drugs Vandetanib (Primary) ; Doxorubicin liposomal
  • Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms ZACFAST
  • Most Recent Events

    • 01 Jun 2013 New source identified and integrated (European Clinical Trials Database, EudraCT2008-005557-38).
    • 18 Feb 2011 Planned end date changed from 1 Feb 2011 to 1 Aug 2010 as reported by ClinicalTrials.gov.
    • 09 Dec 2010 Planned end date changed from 1 Feb 2010 to 1 Feb 2011 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top